Stemline Therapeutics Inc. (STML) Stock Price Down 3%
Stemline Therapeutics Inc. (NASDAQ:STML) dropped 3% during trading on Tuesday . The stock traded as low as $7.43 and last traded at $7.50, with a volume of 52,766 shares trading hands. The stock had previously closed at $7.73.
Several research firms recently issued reports on STML. Jefferies Group reissued a “buy” rating and issued a $23.00 target price on shares of Stemline Therapeutics in a report on Monday, June 6th. Roth Capital reissued a “buy” rating and issued a $32.00 target price on shares of Stemline Therapeutics in a report on Tuesday, May 10th. Zacks Investment Research raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 target price for the company in a report on Wednesday, July 6th. Finally, Wedbush reissued an “outperform” rating and issued a $16.00 target price on shares of Stemline Therapeutics in a report on Tuesday, June 7th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Stemline Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $19.56.
The stock’s 50 day moving average price is $7.14 and its 200 day moving average price is $5.95. The company’s market capitalization is $133.74 million.
Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.03. On average, equities research analysts anticipate that Stemline Therapeutics Inc. will post ($2.14) earnings per share for the current year.
An institutional investor recently raised its position in Stemline Therapeutics stock. Royce & Associates LLC raised its stake in Stemline Therapeutics Inc. (NASDAQ:STML) by 318.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 159,179 shares of the biopharmaceutical company’s stock after buying an additional 121,179 shares during the period. Royce & Associates LLC owned 0.91% of Stemline Therapeutics worth $1,004,000 at the end of the most recent reporting period.
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.